Mazdeh M, Khamseh M, Taheri M, Ghafouri-Fard S. Effect of Rituximab on Expanded Disability Status Scale and Relapse Rate in Multiple Sclerosis Patients. J Mol Neurosci [Internet]. 2020 Aug 1 [cited 2024 Oct 14];70(8):1165–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32144724/

Hu Y, Nie H, Yu HH, Qin C, Wu LJ, Tang ZP, et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Autoimmun Rev [Internet]. 2019 May 1 [cited 2025 May 25];18(5):542–8. Available from: https://pubmed.ncbi.nlm.nih.gov/30844555/

Patricia Mulero LM and XM. Ocrelizumab: a new milestone in multiple sclerosis therapy. Therapeutic Advances in Neurological Disorders Review. 2018;11:11–6.

Hauser SL, Kappos L, Bar-Or A, Wiendl H, Paling D, Williams M, et al. The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment. Neurol Ther. 2023;12(5):1491–1515. https://doi.org/10.1007/s40120-023-00518-0

Martin SJ, Guenette M, Oh J. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy. Drug Des Devel Ther. 2024;18:3025–42.

Aungsumart S, Apiwattanakul M. Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysis. Mult Scler Relat Disord. 2023 May 1;73.

Naismith RT, Cross AH. Further support for rituximab in relapsing multiple sclerosis. Lancet Neurol. 2022;21(8):672–673. https://doi.org/10.1016/S1474-4422(21)00180-0.

Filippini G, Kruja J, Del Giovane C. Rituximab for people with multiple sclerosis. Cochrane Database Syst Rev. 2021 Nov 8;11:CD013874.

Yamout B, Al-Jumah M, Sahraian M, Almalik Y, Al Khaburi J, Shalaby N, et al. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. 2024 [cited 2025 May 25]; Available from: https://doi.org/10.1016/j.msard.2024.105435

Althobaiti AH, Abulaban AA, Bunyan RF, Aldosari FM, AlS-uwaidan FA, Al-Jedai AH, et al. Updated Clinical Recommendations for Multiple Sclerosis by Saudi Neurology Experts. Saudi Journal of Clinical Pharmacy [Internet]. 2024 Jul [cited 2025 May 25];3(3):101–16. Available from: https://journals.lww.com/sjcp/fulltext/2024/03030/updated_clinical_recommendations_for_multiple.1.aspx

Alharbi MA, Aldosari F, Althobaiti AH, Abdullah FM, Al-jarallah S, Alkhawajah NM, et al. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia. BMC Health Serv Res. 2023;23(1):552. https://doi.org/10.1186/s12913-023-09462-z

Rezaee M, Morowvat MH, Poursadeghfard M, Radgoudarzi A, Keshavarz K. Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis. BMC Health Serv Res. 2022;22(1):1415. https://doi.org/10.1186/s12913-022-07495-4.

Yamout BI, Viswanathan S, Laurson-Doube J, Sokhi D. Disease-modifying therapies enter the World Health Organization Essential Medicines List: A victory now requiring a roadmap of implementation. Multiple Sclerosis Journal [Internet]. 2024 Jan 1 [cited 2025 Jul 6];30(1):3–6. Available from: /doi/pdf/10.1177/13524585231205970?download=true

Yamout BI, El-Ayoubi NK, Nicolas J, Kouzi Y El, Khoury SJ, Zeineddine MM. Safety and efficacy of rituximab in multiple sclerosis: A retrospective observational study. J Immunol Res. 2018;2018.

Bribiesca-Contreras E, García-Estrada C, Gómez-Figueroa E, Zertuche-Ortuño L, Rodríguez-Rivas R, Marcín-Sierra M, et al. Impact of rituximab in Mexican patients with Multiple Sclerosis–A single-center retrospective study. Mult Scler Relat Disord. 2022 Feb 1;58.

Almatrafi YM, Babakkor MA, Irfan M, Samkari ET, Alzahrani WM, Mohorjy DK, et al. Efficacy and safety of rituximab in patients with multiple sclerosis An observational study at a tertiary center in Makkah, Saudi Arabia. Neurosciences. 2022 Apr 1;27(2):65–70.

Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology. 2010 Jun 8;74(23):1860–7.

Zhao D, Zhao C, Lu J, Han Y, Sun T, Ren K, et al. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study. Mult Scler Relat Disord. 2023;70:104518. https://doi.org/10.1016/j.msard.2023.104518.

Ghezzi A, Banwell B, Bar-Or A, Chitnis T, Dale RC, Gorman M, et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal [Internet]. 2021 Oct 1 [cited 2025 Jun 4];27(12):1814–22. Available from: https://scispace.com/papers/rituximab-in-patients-with-pediatricmultiple-sclerosis-and-2vhm6ztpeb

Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP. Maximally tolerated versus minimally effective dose: The case of rituximab in multiple sclerosis. Multiple Sclerosis Journal. 2012;18(3):377–8.

Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, et al. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis. 2022 [cited 2025 Jun 4]; Available from: http://links.lww.com/NXI/A770

Claverie R, Perriguey M, Rico A, Boutiere C, Demortiere S, Durozard P, et al. Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing? Neurology(R) neuroimmunology & neuroinflammation. 2023 Aug 21;10(5).

Bellinvia A, Prestipino E, Portaccio E, Razzolini L, Fonderico M, Fratangelo R, et al. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. Neurological Sciences. 2020 Oct 1;41(10):2939–45.

Mokhtari M, Abolmaali M, Emamikhah M, Mohebi N, Hatam J, Amini E, et al. Effectiveness and Safety of Low-dose Rituximab in the treatment of Demyelinating Diseases of the Central Nervous System. 2020 Dec 28 [cited 2025 Jun 6]; Available from: https://scispace.com/papers/

effectiveness-and-safety-of-low-dose-rituximab-in-the-hlnncra2a9

Mathew T, John SK, Kamath V, Murgod U, Thomas K, Baptist AA, et al. Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country. Mult Scler Relat Disord. 2020 Aug 1;43.

Jawad O, Oussama CR. Rituximab for the Treatment of Multiple Sclerosis: A Retrospective Observational Study of 50 Cases from Morocco, and Literature Review. Mathews J Case Rep [Internet]. 2024 Mar 19 [cited 2025 Jun 6];9(3):1–24. Available from: https://www.mathewsopenaccess.com/full-text/rituximab-for-the-treatment-of-multiple-sclerosis-aretrospective-observational-study-of-50-cases-from-morocco-andliterature-review

Seibert J, Blackburn J, Vollmer B, Bennett J, Corboy J, Miravalle A, et al. Safety, Tolerability, and Efficacy of Rituximab in the Treatment of Multiple Sclerosis: 285 Patients Treated in a Single Center. (P3.262). Neurology [Internet]. 2015 Apr 6 [cited 2025 Jun 6];84(14_supplement). Available from: https://scispace.com/papers/safety-tolerability-and-efficacy-ofrituximab-in-the-ehw06scvlcoj

Rommer PS, Patejdl R, Winkelmann A, Benecke R, Zettl UK. Rituximab for secondary progressive multiple sclerosis: A case series. CNS Drugs [Internet]. 2011 [cited 2025 May 25];25(7):607–13. Available from: https://pubmed.ncbi.nlm.nih.gov/21699272/

Naegelin Y, Naegelin P, Von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, et al. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. JAMA Neurol [Internet]. 2019 Mar 1 [cited 2025 May 25];76(3):274–81. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/2719699

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurol [Internet]. 2018 Mar 1;75(3):320–7. Available from: https://doi.org/10.1001/jamaneurol.2017.4011

Rød BE, Høgestøl EA, Torkildsen Ø, Bjørnevik K, Gran JM, Øverås MH, et al. Comparative Effectiveness of Rituximab and Cladribine in Relapsing-Remitting Multiple Sclerosis: A Target Trial Emulation. 2024 Dec 12 [cited 2025 May 25]; Available from: https://scispace.com/papers/comparativeeffectiveness-of-rituximab-and-cladribine-in-62pc28r1p39d

Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol [Internet]. 2019 Sep 6 [cited 2025 May 25];10. Available from: https://pubmed.ncbi.nlm.nih.gov/31555262/

Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 Sep 1;7(9):1477–87.

Khan ZH, Ilyas K, Ghazanfar H, Khan HH, Hussain Q, Hammad S, et al. Fatal Fulminant Hepatitis from Rituximab-induced Hepatitis B Reactivation in a Patient with Follicular Lymphoma: A Case Report and a Brief Review of Literature. Cureus. 2018 Mar 2;

Choon XY, Turley R, Hill S, Jumah W, Kooner P, Kirby M. P64 Screening for hepatitis B prior to commencing rituximab – have we learnt from the past? 2022 Jun;A70–A70.

Dolman G, Theocharopoulos I, Kennedy P. PTU-089 Hepatitis B screening prior to rituximab and subsequent management to reduce the risk of reactivation. 2019 Jun;A235.1–A235.

Cates M, Gut C. SAT0487 Screening for Past Infection with Hepatitis B in Patients Receiving Rituximab: An Audit. Ann Rheum Dis. 2016 Jun;75(Suppl2):847.1–847.

Riedell P, Carson KR. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf. 2014;13(7):977–87.

Pourhadi H, Johnson A, Foote A. AB1618 outcomes of hepatitis b and tuberculosis screening in a cohort of patients on biologic diseasemodifying anti-rheumatic drugs (bdmards) for rheumatic disease at a melbourne public hospital. 2023 Jun;2043.2-2044.

Hackett CB, Wall D, Fitzgerald SF, Rogers S, Kirby B. Varicella-zoster virus immunity in dermatological patients on systemic immunosuppressant treatment. British Journal of Dermatology. 2011 Jun;164(6):1387–9.

Malaiya R, Patel S, Snowden N, Leventis P. Varicella vaccination in the immunocompromised: To give or not to give? Rheumatology (United Kingdom). 2014 Dec 11;54(4):567–9.

Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. Journal of Infectious Diseases. 2008 Mar 1;197(SUPPL. 2).

Otero-Romero S, Rodríguez-García J, Vilella A, Ara JR, Brieva L, Calles C, et al. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurología (English Edition). 2021 Jan;36(1):50–60.

Lebrun C, Vukusic S. Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Mult Scler Relat Disord. 2019 Jun 1;31:173–88.

Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, et al. Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020 Dec 1;20(6):435–45.

Otero-Romero S, Ascherio A, Lebrun-Frénay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol. 2021 Jun 1;34(3):322–8.